Priya Bahri

Dr.
European Medicines Agency
Amsterdam, Noord-Holland, Netherlands

Priya Bahri completed studies in pharmacy (University of Heidelberg) and epidemiology (McGill University) and a PhD in quality management of healthcare (Humboldt University Berlin/Utrecht University). Her continued professional development include post-graduate certificates in strategic health communication (Johns Hopkins University) and global health diplomacy (Graduate Institute Geneva).

She had gained work experience in hospital and community pharmacies and projects for health insurance companies and the German international development agency, before joining the European Medicines Agency (EMA) in 1996. There she has had responsibilities for the co-ordination of the EU pharmacovigilance system and now is the EMA's lead for pharmacovigilance guidelines (EU-GVP) and research into communication and engagement of medicine users in support of evidence-based regulatory decision-making and implementation of risk minimisation in healthcare. In that role she collaborates closely with patient, healthcare professional, academic and industry organisations as well as internationally with non-EU regulators, WHO, UMC, CIOMS and ICH. She regularly provides training sessions for multiple organisations and is associated researcher at the Utrecht Collaborating Centre for Pharmaceutical Policy and Regulation.

As an active member of the International Society of Pharmacoepidemiology (ISPE) she is co-founder of the Special Interest Group on Benefit-Risk Assessment, Communication/risk minimisation and Evaluation (ISPE BRACE SIG), and for the International Society of Pharmacovigilance (ISoP) she is co-founder and coordinator of the Special Interest Group on Medicinal Product Risk Communication (ISoP CommSIG). In 2019, she was awarded as ISoP Fellow.

She is editor of the book “Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research”, published by Springer in 2020.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• Risk Minimization and Communication: Science-based Approaches and Case Studies for Designing and Evaluating Effective Interventions for the Safe Use of Medicinal Products

  Wednesday, August 24, 2022
  8:30 AM – 12:30 PM CEST

• Drug Safety on the Cutting Edge: What are the Implications of EMA's To-Be-Released Risk Minimisation Guidance on Pharmacoepidemiological Methods and Practice in Developed and Developing Countries?

  Saturday, August 27, 2022
  4:15 PM – 5:45 PM CEST

• Updating the Public on COVID-19 Vaccine Safety - Considerations for Pharmacoepidemiologists

  Sunday, August 28, 2022
  10:30 AM – 12:00 PM CEST